Heba Faheem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heba Faheem has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Alaa Elkordy
Tanta University
4 shared publications - Eman H. Basha
Tanta University
4 shared publications - Fatma H. Rizk
Tanta University
3 shared publications - Muhammad Tarek Abdel Ghafar
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt
3 shared publications - Abdallah A. Homouda
Department of Urology, Faculty of Medicine Tanta University Tanta Egypt
2 shared publications - Amira Mostafa Elshamy
Department of Medical Biochemistry, Faculty of Medicine Tanta University Tanta Egypt
2 shared publications
Latest Publications
- 27 August 2025
- Published by Wiley in Comprehensive Physiology
- Vol. 15 (5) , e70039
Nesfatin‐1 Exerts a Neuroprotective Effect in Thioacetamide‐Induced Acute Hepatic Encephalopathy by Activating the PI3K /Akt/Nrf2/ HO ‐1 Pathway
Introduction: Hepatic encephalopathy (HE) is a neuropsychiatric disorder associated with liver failure. Nesfatin‐1 is a neuropeptide characterized by its antioxidant and anti‐inflammatory properties. Aim: This study aimed to evaluate the neuroprotective and hepatoprotective effects of nesfatin‐1 in a thioacetamide (TAA)‐induced rat model of acute HE. Additionally, the study aimed to examine the underlying mechanisms, particularly the role of the PI3K/Akt/Nrf2/HO‐1 signaling pathway. Materials and Methods: Male Sprague Dawley rats were divided into five groups: (1) untreated control, (2) nesfatin‐1‐treated control, (3) thioacetamide‐induced hepatic encephalopathy (HE), (4) HE + nesfatin‐1, and (5) HE + nesfatin‐1 + zinc protoporphyrin IX (ZnPP IX; HO‐1 inhibitor). Assessments included behavioral analysis, serum liver function biomarkers, oxidative stress and inflammatory markers, brain water content, mRNA expression of HO‐1 (Heme Oxygenase 1) and GFAP (Glial Fibrillary Acidic Protein), PI3K/Akt/Nrf2 protein levels, as well as histological and immunohistochemical evaluations. Results: Nesfatin‐1 significantly improved psychomotor activity, reduced serum ALT, AST, total bilirubin, and ammonia levels, and increased albumin. It also lowered brain MDA, TNF‐α, IL‐6, and CRP levels, reduced brain water content, and upregulated the expression of HO‐1 and GFAP. Furthermore, nesfatin‐1 activated the PI3K/Akt/Nrf2 pathway and inhibited the expression of caspase‐3 and NF‐κB in liver and brain tissues. These protective effects were negated by HO‐1 inhibition using ZnppIX. Histological analysis demonstrated the structural integrity of liver and brain tissues in rats treated with nesfatin‐1. Conclusion: Nesfatin‐1 exerts potent hepatoprotective and neuroprotective effects in TAA‐induced hepatic encephalopathy via antioxidative, anti‐inflammatory, and antiapoptotic mechanisms involving the PI3K/Akt/Nrf2/HO‐1 pathway.
- 27 August 2025
- Published by Wiley in Comprehensive Physiology
- Vol. 15 (5) , e70039
Nesfatin‐1 Exerts a Neuroprotective Effect in Thioacetamide‐Induced Acute Hepatic Encephalopathy by Activating the PI3K /Akt/Nrf2/ HO ‐1 Pathway
Introduction: Hepatic encephalopathy (HE) is a neuropsychiatric disorder associated with liver failure. Nesfatin‐1 is a neuropeptide characterized by its antioxidant and anti‐inflammatory properties. Aim: This study aimed to evaluate the neuroprotective and hepatoprotective effects of nesfatin‐1 in a thioacetamide (TAA)‐induced rat model of acute HE. Additionally, the study aimed to examine the underlying mechanisms, particularly the role of the PI3K/Akt/Nrf2/HO‐1 signaling pathway. Materials and Methods: Male Sprague Dawley rats were divided into five groups: (1) untreated control, (2) nesfatin‐1‐treated control, (3) thioacetamide‐induced hepatic encephalopathy (HE), (4) HE + nesfatin‐1, and (5) HE + nesfatin‐1 + zinc protoporphyrin IX (ZnPP IX; HO‐1 inhibitor). Assessments included behavioral analysis, serum liver function biomarkers, oxidative stress and inflammatory markers, brain water content, mRNA expression of HO‐1 (Heme Oxygenase 1) and GFAP (Glial Fibrillary Acidic Protein), PI3K/Akt/Nrf2 protein levels, as well as histological and immunohistochemical evaluations. Results: Nesfatin‐1 significantly improved psychomotor activity, reduced serum ALT, AST, total bilirubin, and ammonia levels, and increased albumin. It also lowered brain MDA, TNF‐α, IL‐6, and CRP levels, reduced brain water content, and upregulated the expression of HO‐1 and GFAP. Furthermore, nesfatin‐1 activated the PI3K/Akt/Nrf2 pathway and inhibited the expression of caspase‐3 and NF‐κB in liver and brain tissues. These protective effects were negated by HO‐1 inhibition using ZnppIX. Histological analysis demonstrated the structural integrity of liver and brain tissues in rats treated with nesfatin‐1. Conclusion: Nesfatin‐1 exerts potent hepatoprotective and neuroprotective effects in TAA‐induced hepatic encephalopathy via antioxidative, anti‐inflammatory, and antiapoptotic mechanisms involving the PI3K/Akt/Nrf2/HO‐1 pathway.
- 2 March 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (3) , e70196
The Protective Effects of Saxagliptin and Cilostazol in an Experimental Model of Cyclophosphamide‐Induced Nephrotoxicity in Rats: Targeting iNOS/NF‐kB and Nrf‐2/HO‐1 Pathways
Cyclophosphamide (CYP) is an extensively used immunosuppressive drug and chemotherapeutic agent for various malignancies. Nevertheless, its use is limited due to adverse effects, including nephrotoxicity. Saxagliptin is a DPP4 inhibitor, while cilostazol serves as an antiplatelet agent. Their nephroprotective effects arise from antioxidant and anti‐inflammatory properties. This study investigated the potential protective effects of Saxagliptin and Cilostazol in rats with kidney damage induced by CYP. Five equal groups of 50 male Wistar rats were randomly categorised as Group I (Control group), Group II: CYP untreated nephrotoxicity–induced group, Group III: Nephrotoxicity‐induced group treated with saxagliptin, Group IV: Nephrotoxicity‐induced group treated with cilostazol, and Group V: Nephrotoxicity‐induced group treated with saxagliptin and cilostazol. Renal tissues and blood samples were collected for biochemical analysis of urea, creatinine, and acute kidney injury biomarkers, including Kim‐1 and NGAL. Additionally, oxidative stress and inflammatory biomarkers such as GSH, MDA, TNF‐α and IL‐1β were assessed, along with gene expression of Nrf‐2/HO‐1 and NF‐kB. Immunohistochemical analysis of iNOS, and histopathological study were also conducted. Saxagliptin and cilostazol ameliorated the nephrotoxicity induced by CYP, as indicated by improvements in urea, creatinine, and acute kidney injury biomarkers Kim‐1 and NGAL. Furthermore, there was a decrease in oxidative stress via the upregulation of Nrf‐2/HO‐1, increased levels of GSH, downregulation of MDA and decreased inflammation via the downregulation of TNF‐α, IL‐1β and iNOS/NF‐kB. The combination of saxagliptin and cilostazol demonstrated a significant improvement compared to using each agent individually. The combination of Saxagliptin/Cilostazol is superior to monotherapy by either of each alone in preventing CYP‐induced nephrotoxicity.
- 2 March 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (3) , e70196
The Protective Effects of Saxagliptin and Cilostazol in an Experimental Model of Cyclophosphamide‐Induced Nephrotoxicity in Rats: Targeting iNOS/NF‐kB and Nrf‐2/HO‐1 Pathways
Cyclophosphamide (CYP) is an extensively used immunosuppressive drug and chemotherapeutic agent for various malignancies. Nevertheless, its use is limited due to adverse effects, including nephrotoxicity. Saxagliptin is a DPP4 inhibitor, while cilostazol serves as an antiplatelet agent. Their nephroprotective effects arise from antioxidant and anti‐inflammatory properties. This study investigated the potential protective effects of Saxagliptin and Cilostazol in rats with kidney damage induced by CYP. Five equal groups of 50 male Wistar rats were randomly categorised as Group I (Control group), Group II: CYP untreated nephrotoxicity–induced group, Group III: Nephrotoxicity‐induced group treated with saxagliptin, Group IV: Nephrotoxicity‐induced group treated with cilostazol, and Group V: Nephrotoxicity‐induced group treated with saxagliptin and cilostazol. Renal tissues and blood samples were collected for biochemical analysis of urea, creatinine, and acute kidney injury biomarkers, including Kim‐1 and NGAL. Additionally, oxidative stress and inflammatory biomarkers such as GSH, MDA, TNF‐α and IL‐1β were assessed, along with gene expression of Nrf‐2/HO‐1 and NF‐kB. Immunohistochemical analysis of iNOS, and histopathological study were also conducted. Saxagliptin and cilostazol ameliorated the nephrotoxicity induced by CYP, as indicated by improvements in urea, creatinine, and acute kidney injury biomarkers Kim‐1 and NGAL. Furthermore, there was a decrease in oxidative stress via the upregulation of Nrf‐2/HO‐1, increased levels of GSH, downregulation of MDA and decreased inflammation via the downregulation of TNF‐α, IL‐1β and iNOS/NF‐kB. The combination of saxagliptin and cilostazol demonstrated a significant improvement compared to using each agent individually. The combination of Saxagliptin/Cilostazol is superior to monotherapy by either of each alone in preventing CYP‐induced nephrotoxicity.
- 1 March 2025
- Published by American Physiological Society in Physiological Genomics
- Vol. 57 (3) , 103-114
Ameliorating immune-dependent inflammation and apoptosis by targeting TLR4/MYD88/NF-κB pathway by celastrol mitigates the diabetic reproductive dysfunction
Celastrol inhibits the production of proinflammatory cytokines in the testicular tissue by specifically targeting the TLR4/MyD88/NF- κB signaling cascade pathways. This indicates that celastrol may serve as a promising new therapeutic target for treating diabetic reproductive dysfunction.
- 1 March 2025
- Published by American Physiological Society in Physiological Genomics
- Vol. 57 (3) , 103-114
Ameliorating immune-dependent inflammation and apoptosis by targeting TLR4/MYD88/NF-κB pathway by celastrol mitigates the diabetic reproductive dysfunction
Celastrol inhibits the production of proinflammatory cytokines in the testicular tissue by specifically targeting the TLR4/MyD88/NF- κB signaling cascade pathways. This indicates that celastrol may serve as a promising new therapeutic target for treating diabetic reproductive dysfunction.
- 27 January 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 991, 177306
The PPAR-α agonist oleoyethanolamide (OEA) ameliorates valproic acid-induced steatohepatitis in rats via suppressing Wnt3a/β-catenin and activating PGC-1α: Involvement of network pharmacology and molecular docking
- 27 January 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 991, 177306
The PPAR-α agonist oleoyethanolamide (OEA) ameliorates valproic acid-induced steatohepatitis in rats via suppressing Wnt3a/β-catenin and activating PGC-1α: Involvement of network pharmacology and molecular docking
- 9 July 2024
- Published by Wiley in The Journal of Physiology
- Vol. 602 (15) , 3621-3639
Ameliorating effects of adropin on letrozole‐induced polycystic ovary syndrome via regulating steroidogenesis and the microbiota inflammatory axis in rats
Growing evidence supports the role of gut microbiota in chronic inflammation, insulin resistance (IR) and sex hormone production in polycystic ovary syndrome (PCOS). Adropin plays a pivotal role in the regulation of glucose and lipid metabolism and is negatively correlated with IR, which affects intestinal microbiota and sex hormones. However, the effect of adropin administration in PCOS has yet to be investigated. The present study aimed to assess the effects of adropin on letrozole (LTZ)‐induced PCOS in rats and the potential underlying mechanisms. The experimental groups were normal, adropin, letrozole and LTZ + adropin. At the end of the experiment, adropin significantly ameliorated PCOS, as evidenced by restoring the normal ovarian structure, decreasing the theca cell thickness in antral follicles, as well as serum testosterone and luteinizing hormone levels and luteinizing hormone/follicle‐stimulating hormone ratios, at the same time as increasing granulosa cell thickness in antral follicles, oestradiol and follicle‐stimulating hormone levels. The ameliorating effect could be attributed to its effect on sex hormone‐binding globulin, key steroidogenic genes STAR and CYP11A1, IR, lipid profile, gut microbiota metabolites–brain–ovary axis components (short chain fatty acids, free fatty acid receptor 3 and peptide YY), intestinal permeability marker (zonulin and tight junction protein claudin‐1), lipopolysaccharides/Toll‐like receptor 4/nuclear factor kappa B inflammatory pathway and oxidative stress makers (malondialdehyde and total antioxidant capacity). In conclusion, adropin has a promising therapeutic effect on PCOS by regulating steroidogenesis, IR, lipid profile, the gut microbiota inflammatory axis and redox homeostasis. image Key points: Adropin treatment reversed endocrine and ovarian morphology disorders in polycystic ovary syndrome (PCOS). Adropin regulated the ovarian steroidogenesis and sex hormone‐binding globulin in PCOS. Adropin improved lipid profile and decreased insulin resistance in PCOS. Adropin modulated the components of the gut–brain–ovary axis (short chain fatty acids, free fatty acid receptor 3 and peptide YY) in PCOS. Adropin improved intestinal barrier integrity, suppressed of lipopolysaccharides/Toll‐like receptor 4/nuclear factor kappa B signalling pathway and oxidative stress in PCOS.
- 9 July 2024
- Published by Wiley in The Journal of Physiology
- Vol. 602 (15) , 3621-3639
Ameliorating effects of adropin on letrozole‐induced polycystic ovary syndrome via regulating steroidogenesis and the microbiota inflammatory axis in rats
Growing evidence supports the role of gut microbiota in chronic inflammation, insulin resistance (IR) and sex hormone production in polycystic ovary syndrome (PCOS). Adropin plays a pivotal role in the regulation of glucose and lipid metabolism and is negatively correlated with IR, which affects intestinal microbiota and sex hormones. However, the effect of adropin administration in PCOS has yet to be investigated. The present study aimed to assess the effects of adropin on letrozole (LTZ)‐induced PCOS in rats and the potential underlying mechanisms. The experimental groups were normal, adropin, letrozole and LTZ + adropin. At the end of the experiment, adropin significantly ameliorated PCOS, as evidenced by restoring the normal ovarian structure, decreasing the theca cell thickness in antral follicles, as well as serum testosterone and luteinizing hormone levels and luteinizing hormone/follicle‐stimulating hormone ratios, at the same time as increasing granulosa cell thickness in antral follicles, oestradiol and follicle‐stimulating hormone levels. The ameliorating effect could be attributed to its effect on sex hormone‐binding globulin, key steroidogenic genes STAR and CYP11A1, IR, lipid profile, gut microbiota metabolites–brain–ovary axis components (short chain fatty acids, free fatty acid receptor 3 and peptide YY), intestinal permeability marker (zonulin and tight junction protein claudin‐1), lipopolysaccharides/Toll‐like receptor 4/nuclear factor kappa B inflammatory pathway and oxidative stress makers (malondialdehyde and total antioxidant capacity). In conclusion, adropin has a promising therapeutic effect on PCOS by regulating steroidogenesis, IR, lipid profile, the gut microbiota inflammatory axis and redox homeostasis. image Key points: Adropin treatment reversed endocrine and ovarian morphology disorders in polycystic ovary syndrome (PCOS). Adropin regulated the ovarian steroidogenesis and sex hormone‐binding globulin in PCOS. Adropin improved lipid profile and decreased insulin resistance in PCOS. Adropin modulated the components of the gut–brain–ovary axis (short chain fatty acids, free fatty acid receptor 3 and peptide YY) in PCOS. Adropin improved intestinal barrier integrity, suppressed of lipopolysaccharides/Toll‐like receptor 4/nuclear factor kappa B signalling pathway and oxidative stress in PCOS.
- Open Access
- 10 August 2023
- Published by Springer Nature in Pflügers Archiv - European Journal of Physiology
- Vol. 475 (10) , 1161-1176
Ulinastatin ameliorated streptozotocin-induced diabetic nephropathy: Potential effects via modulating the components of gut-kidney axis and restoring mitochondrial homeostasis
Growing evidence supports the role of the gut-kidney axis and persistent mitochondrial dysfunction in the pathogenesis of diabetic nephropathy (DN). Ulinastatin (UTI) has a potent anti-inflammatory effect, protecting the kidney and the gut barrier in sepsis, but its effect on DN has yet to be investigated. This study aimed to assess the potential mitigating effect of UTI on DN and investigate the possible involvement of gut-kidney axis and mitochondrial homeostasis in this effect. Forty male Wistar rats were divided equally into four groups: normal; UTI-treated control; untreated DN; and UTI-treated DN. At the end of the experiment, UTI ameliorated DN by modulating the gut-kidney axis as it improved serum and urinary creatinine, urine volume, creatinine clearance, blood urea nitrogen, urinary albumin, intestinal morphology including villus height, crypt depth, and number of goblet cells, with upregulating the expression of intestinal tight-junction protein claudin-1, and counteracting kidney changes as indicated by significantly decreasing glomerular tuft area and periglomerular and peritubular collagen deposition. In addition, it significantly reduced intestinal and renal nuclear factor kappa B (NF-κB), serum Complement 5a (C5a), renal monocyte chemoattractant protein-1 (MCP-1), renal intercellular adhesion molecule 1 (ICAM1), and renal signal transducer and activator of transcription 3 (STAT3), mitochondrial dynamin related protein 1 (Drp1), mitochondrial fission 1 protein (FIS1), mitochondrial reactive oxygen species (ROS), renal hydrogen peroxide (H2O2), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels. Furthermore, it significantly increased serum short chain fatty acids (SCFAs), and mitochondrial ATP levels and mitochondrial transmembrane potential. Moreover, there were significant correlations between measured markers of gut components of the gut-kidney axis and renal function tests in UTI-treated DN group. In conclusion, UTI has a promising therapeutic effect on DN by modulating the gut-kidney axis and improving renal mitochondrial dynamics and redox equilibrium.
- 10 August 2023
- Published by Springer Nature in Pflügers Archiv - European Journal of Physiology
- Vol. 475 (10) , 1161-1176
Open AccessUlinastatin ameliorated streptozotocin-induced diabetic nephropathy: Potential effects via modulating the components of gut-kidney axis and restoring mitochondrial homeostasis
Growing evidence supports the role of the gut-kidney axis and persistent mitochondrial dysfunction in the pathogenesis of diabetic nephropathy (DN). Ulinastatin (UTI) has a potent anti-inflammatory effect, protecting the kidney and the gut barrier in sepsis, but its effect on DN has yet to be investigated. This study aimed to assess the potential mitigating effect of UTI on DN and investigate the possible involvement of gut-kidney axis and mitochondrial homeostasis in this effect. Forty male Wistar rats were divided equally into four groups: normal; UTI-treated control; untreated DN; and UTI-treated DN. At the end of the experiment, UTI ameliorated DN by modulating the gut-kidney axis as it improved serum and urinary creatinine, urine volume, creatinine clearance, blood urea nitrogen, urinary albumin, intestinal morphology including villus height, crypt depth, and number of goblet cells, with upregulating the expression of intestinal tight-junction protein claudin-1, and counteracting kidney changes as indicated by significantly decreasing glomerular tuft area and periglomerular and peritubular collagen deposition. In addition, it significantly reduced intestinal and renal nuclear factor kappa B (NF-κB), serum Complement 5a (C5a), renal monocyte chemoattractant protein-1 (MCP-1), renal intercellular adhesion molecule 1 (ICAM1), and renal signal transducer and activator of transcription 3 (STAT3), mitochondrial dynamin related protein 1 (Drp1), mitochondrial fission 1 protein (FIS1), mitochondrial reactive oxygen species (ROS), renal hydrogen peroxide (H2O2), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels. Furthermore, it significantly increased serum short chain fatty acids (SCFAs), and mitochondrial ATP levels and mitochondrial transmembrane potential. Moreover, there were significant correlations between measured markers of gut components of the gut-kidney axis and renal function tests in UTI-treated DN group. In conclusion, UTI has a promising therapeutic effect on DN by modulating the gut-kidney axis and improving renal mitochondrial dynamics and redox equilibrium.
- 1 June 2019
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 64, 206-213
Neuroprotective effects of minocycline and progesterone on white matter injury after focal cerebral ischemia
- 1 June 2019
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 64, 206-213
Neuroprotective effects of minocycline and progesterone on white matter injury after focal cerebral ischemia